InvestorsHub Logo
Followers 467
Posts 26915
Boards Moderated 2
Alias Born 09/11/2006

Re: surf1944 post# 522

Wednesday, 09/12/2012 11:59:35 AM

Wednesday, September 12, 2012 11:59:35 AM

Post# of 535
8:23AM On The Wires (WIRES) :Transcept Pharmaceuticals (TSPT) has completed enrollment in its Phase 2 clinical trial evaluating TO-2061 added as adjunctive therapy for patients with obsessive compulsive disorder who have not adequately responded to first-line treatment with an approved OCD medication. The co plans to announce top-line results of this study in 1Q2013.